In a phase Ib clinical trial in cases of borderline resectable and locally advanced pancreatic cancer, PF-04136309—an orally available small-molecule CCR2 inhibitor—significantly reduced bone marrow monocyte recruitment into peripheral blood. This evidence concerns the gene CCR2 and familial pancreatic carcinoma.